エストロゲンは,ERα- Tau結合を阻害することによって,セボフルラン誘発の神経毒性を軽減する
Feixiang Li1,2, Bingqing Gong1, Zichen Song1
1Department of Anesthesiology, Tianjin Medical University General Hospital, Tianjin Institute of Anesthesiology, Tianjin, 300052, China.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
|September 6, 2025
まとめ
エストロゲンは,エストロゲン受容体アルファ-タウの相互作用を調節することによって,雌マウスのセボフルランの神経毒性から保護します. この発見は麻酔によるリスクを理解し,標的を絞った介入策を策定する上で極めて重要です.
科学分野:
- 神経科学
- 麻酔科
- 内分泌学
背景:
- セボフルランの神経毒性は年齢に依存し,性差およびエストロゲンの役割は不明である.
- 既存の研究は テストステロンの保護効果を強調していますが 麻酔による神経毒性に対するエストロゲンの影響は 調査が必要です
研究 の 目的:
- 異なる年齢層のマウスの神経毒性に対するセボフルランの性特異的効果を調査する.
- セボフルランによる神経毒性の軽減におけるエストロゲンとその受容体アルファ (ERα) の役割を解明する.
主な方法:
- 脊椎海馬CA1領域におけるタウリン酸化,認知機能,神経構造的整合性を含む神経毒性マーカーの評価.
- エストロゲン受容体アンタゴニスト,阻害剤,過剰発現のためのウイルスベクター,ERαノックアウトモデル,GRAMMドッキング,ITC,および競争力のあるELISAをメカニズムを探索するために利用した.
主要な成果:
- セボフルランは中年の雌マウスの神経毒性を誘発したが,雄マウスは誘発しなかった. エストロゲン投与は,タウリン酸化,認知障害,神経信号伝達/構造変化を改善した.
- エストロゲンの保護効果はERαに依存し,ERαノックアウトマウスの利益の廃止によって示された.
- 高齢の女性では,エストロゲンの保護効果はERαのアップレギュレーションに依存し,エストロゲンとタウは競争的にERαに結合し,セボフルランによって強化された相互作用であることが判明しました.
結論:
- エストロゲンは,セボフルランによる神経毒性に対する保護効果を,性別および年齢に応じて発揮する.
- エストロゲンは主にERα- Tau相互作用の調節によってセボフルランの神経毒性を軽減し,潜在的な治療目標を提供することを示しています.
さらに関連する動画
04:56In Vitro Method to Control Concentrations of Halogenated Gases in Cultured Alveolar Epithelial Cells
Published on: October 23, 2018
6.7K
03:02Application of Dixon's Up-and-Down Design to Estimate the Minimum Alveolar Concentration of Sevoflurane in Rats with Refined Movement Classification
Published on: July 25, 2025
106
関連する概念動画
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
439
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
439
01:21Drugs Affecting Neurotransmitter Release or Uptake
1.2K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.2K
01:26Anxiolytic Drugs: Overview
479
Anxiolytic drugs are vital in managing anxiety disorders by effectively alleviating symptoms such as excessive fear, tachycardia, and tremors. There are several classes of anxiolytic medications, each with unique mechanisms of action and potential side effects.
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic...
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic...
479
01:29Drugs Affecting Neurotransmitter Synthesis
1.6K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.6K
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
632
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
632
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
236
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
236